G1 Therapeutics, Inc. (GTHX)
Largest Insider Buys in Sector
GTHX Stock Price History Chart
GTHX Stock Performance
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Insider Activity of G1 Therapeutics, Inc.
Over the last 12 months, insiders at G1 Therapeutics, Inc. have bought $0 and sold $990,019 worth of G1 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at G1 Therapeutics, Inc. have bought $1.58M and sold $3.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $1.35M was made by MUIR GLENN P (director) on 2020‑11‑18.
List of Insider Buy and Sell Transactions, G1 Therapeutics, Inc.
| 2024-05-23 | Sale | Thomas Monica R. | Chief Legal & People Officer | 5,826 0.0113% | $4.27 | $24,864 | -29.29% | |
| 2024-05-13 | Sale | Bailey John E. (Jack) Jr. | President and CEO | 37,258 0.0739% | $4.79 | $178,421 | -30.30% | |
| 2024-05-13 | Sale | Avagliano Mark | Chief Business Officer | 8,151 0.0162% | $4.79 | $39,034 | -30.30% | |
| 2024-05-13 | Sale | Malik Rajesh | Chief Medical Officer | 8,151 0.0162% | $4.79 | $39,034 | -30.30% | |
| 2024-05-13 | Sale | Umstead John W. V | Chief Financial Officer | 8,151 0.0162% | $4.79 | $39,034 | -30.30% | |
| 2024-05-13 | Sale | MURDOCK TERRY L | Chief Operating Officer | 8,151 0.0162% | $4.79 | $39,034 | -30.30% | |
| 2024-05-13 | Sale | Perry Andrew | Chief Commercial Officer | 8,151 0.0162% | $4.79 | $39,034 | -30.30% | |
| 2024-03-18 | Sale | Umstead John W. V | Chief Financial Officer | 6,547 0.0118% | $3.02 | $19,752 | +28.82% | |
| 2024-02-12 | Sale | Malik Rajesh | Chief Medical Officer | 28,600 0.0574% | $4.62 | $132,143 | -17.19% | |
| 2024-01-04 | Sale | Malik Rajesh | Chief Medical Officer | 721 0.0013% | $2.94 | $2,121 | +18.41% | |
| 2024-01-04 | Sale | Umstead John W. V | Chief Financial Officer | 111 0.0002% | $2.94 | $327 | +18.41% | |
| 2024-01-04 | Sale | Avagliano Mark | Chief Business Officer | 721 0.0013% | $2.94 | $2,121 | +18.41% | |
| 2024-01-04 | Sale | MURDOCK TERRY L | Chief Operating Officer | 721 0.0013% | $2.94 | $2,121 | +18.41% | |
| 2024-01-03 | Sale | Bailey John E. (Jack) Jr. | President and CEO | 11,686 0.0235% | $3.12 | $36,447 | +24.83% | |
| 2024-01-03 | Sale | Malik Rajesh | Chief Medical Officer | 3,019 0.0061% | $3.12 | $9,416 | +24.83% | |
| 2024-01-03 | Sale | Umstead John W. V | Chief Financial Officer | 632 0.0013% | $3.12 | $1,971 | +24.83% | |
| 2024-01-03 | Sale | Avagliano Mark | Chief Business Officer | 3,360 0.0068% | $3.12 | $10,480 | +24.83% | |
| 2024-01-03 | Sale | MURDOCK TERRY L | Chief Operating Officer | 3,019 0.0061% | $3.12 | $9,416 | +24.83% | |
| 2024-01-03 | Sale | Perry Andrew | Chief Commercial Officer | 2,413 0.0049% | $3.12 | $7,526 | +24.83% | |
| 2024-01-02 | Sale | Bailey John E. (Jack) Jr. | President and CEO | 32,983 0.0674% | $3.27 | $108,006 | +19.07% |
Insider Historical Profitability
| Bailey John E. (Jack) Jr. | President and CEO | 452336 0.9444% | $2.25 | 2 | 7 | +56.12% |
| Malik Rajesh | Chief Medical Officer | 161787 0.3278% | $2.25 | 0 | 28 | |
| Umstead John W. V | Chief Financial Officer | 153245 0.2516% | $2.25 | 0 | 4 | |
| Avagliano Mark | Chief Business Officer | 209683 0.2273% | $2.25 | 0 | 4 | |
| Velleca Mark A. | director | 116000 0.2237% | $2.25 | 0 | 36 | |
| Thomas Monica R. | Chief Legal & People Officer | 109825 0.2101% | $2.25 | 0 | 1 | |
| MURDOCK TERRY L | Chief Operating Officer | 95487 0.1999% | $2.25 | 0 | 13 | |
| Perry Andrew | Chief Commercial Officer | 78951 0.168% | $2.25 | 0 | 4 | |
| Eshelman Ventures, LLC | 10 percent owner | 3439151 6.6337% | $2.25 | 1 | 0 | +29.51% |
| Thorp Clay | 10 percent owner | 3237711 6.2451% | $2.25 | 1 | 4 | +29.51% |
| MedImmune Ventures, Inc. | 10 percent owner | 2950630 5.6914% | $2.25 | 2 | 3 | +35.86% |
| RA CAPITAL MANAGEMENT, LLC | 2684244 5.1776% | $2.25 | 1 | 0 | +29.51% | |
| ESHELMAN FREDRIC N | 250000 0.4822% | $2.25 | 2 | 0 | +67.27% | |
| MUIR GLENN P | director | 170969 0.3298% | $2.25 | 2 | 0 | +45.69% |
| Moses Jennifer K. | CFO | 57820 0.1115% | $2.25 | 0 | 15 | |
| Strum Jay | Chief Scientific Officer | 48569 0.0937% | $2.25 | 0 | 2 | |
| Hanson James S. | General Counsel | 41087 0.0793% | $2.25 | 3 | 3 | +4.42% |
| DEMAREE JOHN | Chief Commercial Officer | 5250 0.0101% | $2.25 | 1 | 0 | <0.0001% |
| RUDNICK SETH | director | 4389 0.0085% | $2.25 | 0 | 13 | |
| Schwalm Cynthia | director | 1500 0.0029% | $2.25 | 1 | 0 | +14.5% |
| PHILLIPS BARCLAY A | SVP & Chief Financial Officer | 0 0% | $2.25 | 0 | 1 |
Institutional Investor Ownership
| The Vanguard Group | $8.99M | 3.98 | 2.08M | +5.04% | +$431,567.98 | <0.0001 | |
| Susquehanna International Group | $4.11M | 1.82 | 950,839 | -39.77% | -$2.71M | <0.01 | |
| Renaissance Technologies | $3.9M | 1.73 | 903,700 | +43.35% | +$1.18M | 0.01 | |
| Raymond James Associates | $3.47M | 1.54 | 802,835 | +41.95% | +$1.03M | <0.01 | |
| D. E. Shaw & Co. | $3.39M | 1.5 | 785,259 | +58.49% | +$1.25M | 0.01 | |
| BlackRock | $2.9M | 1.29 | 672,027 | -1.27% | -$37,311.85 | <0.0001 | |
| Geode Capital Management | $2.19M | 0.97 | 505,805 | +9.77% | +$194,573.61 | <0.0001 | |
| Goldman Sachs | $1.94M | 0.86 | 447,961 | +3,808.23% | +$1.89M | <0.0001 | |
| Millennium Management LLC | $1.93M | 0.85 | 445,912 | +1,336.3% | +$1.79M | <0.01 | |
| Acadian Asset Management | $1.87M | 0.83 | 433,709 | +643.23% | +$1.62M | 0.01 | |
| Standard Life | $1.83M | 0.81 | 423,869 | 0% | +$0 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $1.79M | 0.79 | 413,579 | +115.28% | +$956,745.93 | <0.01 | |
| Bank of America | $1.64M | 0.73 | 379,011 | +35.62% | +$430,064.50 | <0.0001 | |
| Jacobs Levy Equity Management | $1.63M | 0.72 | 377,858 | +20.7% | +$279,892.88 | 0.01 | |
| Two Sigma | $1.44M | 0.64 | 334,131 | +106.17% | +$743,333.80 | <0.01 | |
| Jane Street Capital | $1.44M | 0.64 | 333,572 | +49.85% | +$479,399.03 | <0.01 | |
| Qube Research & Technologies | $1.4M | 0.62 | 324,466 | +586.03% | +$1.2M | <0.01 | |
| Man Group Plc | $1.19M | 0.53 | 275,358 | +87.75% | +$555,949.65 | <0.01 | |
| Group One Trading | $988,891.00 | 0.44 | 228,910 | -56.09% | -$1.26M | 0.03 | |
| Bridgeway Capital Management | $825,738.00 | 0.37 | 191,143 | +59.29% | +$307,337.85 | 0.02 | |
| Two Sigma Advisers LP | $793,584.00 | 0.35 | 183,700 | +38.33% | +$219,888.00 | <0.01 | |
| Needham Investment Management LLC | $777,600.00 | 0.34 | 180,000 | 0% | +$0 | 0.07 | |
| Level Four Advisory Services Llc | $544,730.00 | 0.34 | 178,600 | 0% | +$0 | 0.02 | |
| Cubist Systematic Strategies | $759,383.00 | 0.34 | 175,783 | +719.77% | +$666,749.19 | 0.01 | |
| Morgan Stanley | $757,456.00 | 0.34 | 175,337 | +3.1% | +$22,805.28 | <0.0001 | |
| State Street | $695,978.00 | 0.31 | 161,106 | 0% | +$0 | <0.0001 | |
| Hrt Financial Llc | $608,000.00 | 0.27 | 140,909 | New | +$608,000.00 | <0.01 | |
| Citigroup | $557,565.00 | 0.25 | 129,066 | +50.17% | +$186,265.40 | <0.0001 | |
| Northern Trust | $542,217.00 | 0.24 | 125,513 | <0.01% | -$47.52 | <0.0001 | |
| Squarepoint Ops LLC | $454,274.00 | 0.2 | 105,156 | +548.39% | +$384,212.23 | <0.01 | |
| FinTrust Capital Advisors, LLC | $435,370.00 | 0.19 | 100,780 | 0% | +$0 | 0.08 | |
| Caption Management Llc | $421,494.00 | 0.19 | 97,568 | New | +$421,494.00 | 0.01 | |
| Denali Advisors | $371,952.00 | 0.17 | 86,100 | -29.31% | -$154,224.00 | 0.11 | |
| Franklin Street Advisors Inc Nc | $360,000.00 | 0.16 | 83,400 | 0% | +$0 | 0.03 | |
| Birchview Capital Lp | $345,600.00 | 0.15 | 80,000 | 0% | +$0 | 0.02 | |
| Dimensional Fund Advisors | $334,933.00 | 0.15 | 77,531 | +1.13% | +$3,736.79 | <0.0001 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $305,835.00 | 0.14 | 70,795 | New | +$305,835.00 | 0.01 | |
| Fidelity Investments | $258,941.00 | 0.12 | 59,940 | -2.24% | -$5,935.69 | <0.0001 | |
| JPMorgan Chase | $236,019.00 | 0.1 | 54,634 | +21,753.6% | +$234,939.00 | <0.0001 | |
| Brevan Howard Capital Management Lp | $205,394.00 | 0.09 | 47,545 | New | +$205,394.00 | 0.02 | |
| Beacon Pointe Advisors Llc | $188,784.00 | 0.08 | 43,700 | 0% | +$0 | <0.01 | |
| Creative Financial Designs Inc Adv | $174,982.00 | 0.08 | 40,505 | +14.81% | +$22,572.05 | 0.02 | |
| Ameriprise Financial | $153,360.00 | 0.07 | 35,500 | 0% | +$0 | <0.0001 | |
| Envestnet Asset Management Inc | $153,019.00 | 0.07 | 35,421 | +27.96% | +$33,436.86 | <0.0001 | |
| Rsm Us Wealth Management Llc | $152,211.00 | 0.07 | 35,234 | 0% | +$0 | <0.01 | |
| American Century Investments | $149,679.00 | 0.07 | 34,648 | +111.51% | +$78,913.25 | <0.0001 | |
| Raymond James Financial Services Advisors Inc | $135,696.00 | 0.06 | 31,411 | -6.84% | -$9,970.59 | <0.0001 | |
| Wells Fargo | $134,201.00 | 0.06 | 31,065 | +37.71% | +$36,750.29 | <0.0001 | |
| Capstone Investment Advisors | $117,720.00 | 0.05 | 27,250 | +9% | +$9,720.00 | <0.01 | |
| Y Intercept Hong Kong Ltd | $115,357.00 | 0.05 | 26,703 | +26.43% | +$24,114.25 | 0.01 |